Genelux Corporation (GNLX)
NASDAQ: GNLX · IEX Real-Time Price · USD
3.260
-0.060 (-1.81%)
Apr 26, 2024, 3:20 PM EDT - Market open
Company Description
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate.
The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Genelux Corporation
| Country | United States |
| Founded | 2001 |
| IPO Date | Jan 26, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Thomas Zindrick J.D. |
Contact Details
Address: 2625 Townsgate Road, Suite 230 Westlake Village, California 91361 United States | |
| Phone | 805-267-9889 |
| Website | genelux.com |
Stock Details
| Ticker Symbol | GNLX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001231457 |
| ISIN Number | US36870H1032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas Zindrick J.D. | Chairman, Chief Executive Officer and President |
| Lourie S. Zak | Chief Financial Officer |
| Caroline Jewett | Vice President and Head of Quality |
| Dr. Joseph Cappello Ph.D. | Chief Technical Officer |
| Sean Ryder J.D. | General Counsel and Corporate Secretary |
| Dr. Yong Yu Ph.D. | Senior Vice President of Clinical Development |
| Prof. Paul Scigalla M.D., Ph.D. | Chief Medical Officer |
| Ralph Smalling B.Sc. | Vice President and Head of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 144/A | Filing |
| Apr 11, 2024 | 144 | Filing |
| Apr 9, 2024 | 8-K | Current Report |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 29, 2024 | 10-K | Annual Report |
| Feb 13, 2024 | EFFECT | Notice of Effectiveness |
| Feb 8, 2024 | UPLOAD | Filing |
| Feb 5, 2024 | 8-K | Current Report |
| Feb 2, 2024 | 8-K | Current Report |